Hemodynamic Responses to Dobutamine, Hydralazine and Sodium Nitroprusside Following Pentastarch Infusion during Cardiac Tamponade in Dogs.
10.4097/kjae.1998.35.5.852
- Author:
Jin Mo KIM
;
Jung Ho LEE
;
Young Ho JANG
;
Jae Kyu CHEUN
- Publication Type:Original Article
- Keywords:
Heart: tamponade;
cardica output;
Phamacology: dobutamine;
hydralazine;
nitroprusside
- MeSH:
Animals;
Arterial Pressure;
Atrial Pressure;
Blood Pressure;
Blood Volume;
Cardiac Output;
Cardiac Tamponade*;
Cardiotonic Agents;
Dobutamine*;
Dogs*;
Heart Rate;
Hemodynamics*;
Hydralazine*;
Hydroxyethyl Starch Derivatives*;
Nitroprusside*;
Plasma;
Vasodilator Agents
- From:Korean Journal of Anesthesiology
1998;35(5):852-860
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Background: Cardiac tamponade results in a hemodynamic disorder associated with decreased cardiac output and blood pressure. To improve cardiac output in a subject with cardiac tamponade, cardiotonic drugs and vasodilators with blood volume expander can be used. The purpose of this study was to observe the hemodynamic effects of cardiotonic drugs and vasodilators following administration of plasma expander in the dogs with cardiac tamponade. Method: Three groups of dogs were studied during the induced cardiac tamponade. Following infusion of pentastarch, group I received dobutamine by dripping of 10 microg/kg/min, followed by injection of 20 microg/kg/min, group II received hydralazine (20 mg, 40 mg) and group III received sodium nitroprusside (5 microg/kg/min, 10 microg/kg/min). The heart rate, blood pressure, cardiac output and pulmonary arterial occluded pressure were measured. The atrial transmural pressure was calculated by subtracting intrapericardial pressure from mean atrial pressure. Results: Cardiac output was increased in the groups I and II, but mean arterial pressure was increased in only the group I. Atrial transmural pressure was not changed in all three groups. Conclusion: The most pronounced hemodynamic improvements during the cardiac tamponade is observed in group I with pentastarch-dobutamine combination.
